articles
- Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. 18:1335-1350. 2016
- Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. 16:392-399. 2014
- Mechanism-based pharmacokinetic/pharmacodynamic modeling of rat prefrontal cortical dopamine response to dual acting norepinephrine reuptake inhibitor and 5-HT1A partial agonist. 14:365-376. 2012
- Neuropeptidomic components generated by proteomic functions in secretory vesicles for cell-cell communication. 12:635-645. 2010
- Peptidomics of the prolyl peptidases. 12:483-491. 2010
- PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. 11:395-405. 2009
- Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. 11:342-352. 2009
- PTD-mediated loading of tumor-seeking lymphocytes with prodrug-activating enzymes. 10:614-621. 2008
- Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase). 10:439-449. 2008
- Development, validation, and clinical implementation of an assay to measure total antibody response to Naglazyme (galsulfase). 10:363-372. 2008
- Mu opioid receptor regulation and opiate responsiveness. 7:E587-E591. 2005